Kras G12c | search
Click here to view Kras G12c news from 60+ newspapers.
Bookmark or Share- FDA grants accelerated approval to adagrasib for KRAS G12C-mutated ...On December 12, 2022, the Food and Drug Administration (FDA) granted accelerated approval to adagrasib (Krazati, Mirati Therapeutics, Inc.), a RAS GTPase family inhibitor, for adult patients with...
- Tackling KRAS G12C -mutated non-small-cell lung cancer: iteration and ...of an allosteric drug-binding pocket in GDP-bound KRAS G12C (ie, Gly12Cys) has led to accelerated approvals by the US Food and Drug Administration for the use of two covalent inhibitors, sotorasib and adagrasib, post chemoimmunotherapy in advanced KRAS G12C-mutated non-small-cell lung cancers (NSCLCs).This breakthrough has ushered in a new era of RAS drug discovery.
- KRAS G12C Inhibition with Sotorasib in Advanced Solid TumorsWe conducted a phase 1, multicenter, open-label trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation. The trial consisted of dose escalation and...
- Targeting KRAS in cancer | Nature MedicineThe first successes occurred with allele-specific targeting of KRAS p.Gly12Cys (G12C) in non-small cell lung cancer, resulting in regulatory approval of two agents—sotorasib and adagrasib.
- KRAS G12C Mutations in NSCLC: From Target to ResistanceA better understanding of the role of KRAS and its different mutations has led to the development of specific small-molecule inhibitors able to target KRAS G12C, an oncogenic driver mutation in a number of cancers, including non-small cell lung cancer.
More
